Satellos Announces First Participant With Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

BusinesswireDec 11 07:00 ET

Satellos to Participate in Oppenheimer Movers in Rare Disease Summit

BusinesswireDec 3 07:00 ET

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

BusinesswireDec 2 07:00 ET

Satellos Appoints Stephanie Brown to Board of Directors

BusinesswireNov 14 07:00 ET

Satellos Bioscience Q3 Loss Widens on Higher R&D Expenses

MT NewswiresNov 13 08:13 ET

Satellos Bioscience Inc: INTERIM MDA EN

SEDARNov 13 07:18 ET · Announcements